Skip to main content
CELC
NASDAQ Industrial Applications And Services

Celcuity Reports Q1 Loss Beat, Expands Pivotal VIKTORIA-2 Trial for Gedatolisib

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$129.58
Mkt Cap
$6.512B
52W Low
$9.51
52W High
$151.02
52W Position info
1263% above low
Off High info
14% below high
Rel. Volume info
2.6× avg
Market data snapshot near publication time

CELC has more than doubled off its 52-week low of $9.51 on elevated volume (2.6× avg).

Summary

Celcuity Inc. reported a smaller-than-expected Q1 loss and significantly expanded its Phase 3 VIKTORIA-2 trial, broadening the potential market for its lead drug candidate, gedatolisib.


Key Events · Product Development and Regulatory · CELC

  • Q1 2026 Financial Results Beat Expectations

    Celcuity reported a smaller-than-expected Q1 loss, with adjusted EPS of -$0.86 significantly beating consensus estimates. Net cash used in operating activities increased to $55.1 million, with $387.1 million in cash and investments, providing a runway through 2027.

  • Pivotal VIKTORIA-2 Trial Expanded

    The Phase 3 VIKTORIA-2 clinical trial was expanded to include a second study (Study 2) evaluating gedatolisib as first-line treatment in patients with endocrine-sensitive HR+/HER2- advanced breast cancer, significantly broadening the drug's potential market.

  • Subcutaneous Formulation Development Initiated

    Development of a subcutaneous formulation for gedatolisib is underway, with the first patent application submitted. This aims to provide a more convenient injection alternative to infusion, supporting long-term lifecycle development.

  • FDA PDUFA Date Confirmed

    The FDA's Priority Review and PDUFA goal date of July 17, 2026, for gedatolisib's New Drug Application (NDA) in HR+/HER2- PIK3CA wild-type ABC was reconfirmed.


Analysis · CELC · Industrial Applications And Services

This 8-K is highly important as it delivers a positive earnings surprise, with the company's adjusted Q1 loss beating analyst expectations. More critically, Celcuity announced a significant expansion of its pivotal Phase 3 VIKTORIA-2 trial to include a large, previously untapped patient population for first-line treatment of endocrine-sensitive breast cancer. This strategic move substantially increases the future market opportunity for gedatolisib. The company also confirmed its PDUFA date for another gedatolisib indication and is developing a more convenient subcutaneous formulation, reinforcing its long-term pipeline strategy.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CELC was trading at $129.58 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $9.51 to $151.02. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CELC - Latest Insights

CELC
Nov 09, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $66.32
Real-time Price: $55.59 info
Change: -$10.73 (-16%) info
Market Cap: $2.731B info
CELC
Nov 05, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $55.59 info
Change: -$8.45 (-13%) info
Market Cap: $2.731B info
CELC
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $55.59 info
Change: -$8.45 (-13%) info
Market Cap: $2.731B info
CELC
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $55.59 info
Change: -$8.45 (-13%) info
Market Cap: $2.731B info
CELC
Sep 30, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.00
Real-time Price: $55.59 info
Change: -$23.41 (-30%) info
Market Cap: $2.731B info